Newly described cysteine synthesis backup pathway may help cancer cells resist treatment

Researchers have described a backup biochemical pathway that allows mammalian cells to synthesise cysteine even when the routes considered essential for this process are pharmacologically or genetically disabled. The work, reported via ScienceDaily, identifies what the authors describe as a surprising cellular survival mechanism — one that operates independently of the two pathways previously thought to be indispensable for cysteine production in mammalian cells.

Cysteine is required for the synthesis of glutathione, the cell's principal antioxidant buffer. Several cancer therapeutic strategies under investigation aim to deplete tumour cells of glutathione by blocking cysteine uptake or synthesis, thereby inducing a form of oxidative cell death known as ferroptosis. If tumour cells can activate this alternative cysteine synthesis route, they may be able to maintain glutathione levels and resist such approaches.

The researchers suggest that inhibiting this newly described backup pathway could potentially sensitise cancer cells to treatments that already target cysteine metabolism. The source report does not specify the institution, research team, or journal of record; accordingly, this summary is based on secondary reporting from ScienceDaily and the underlying primary publication has not been independently verified. Readers are encouraged to locate the primary paper before drawing further conclusions. The finding is at an early, mechanistic stage and does not have direct translational implications at this time.